Companies in #Epidermolysis bullosa
Found 1 company operating in this sector.
Commercial-stage cell and gene therapy company. Its ZEVASKYN (prademagene zamikeracel) autologous cell sheet was approved by the FDA in April 2025 for recessive dystrophic epidermolysis bullosa, and FAYUVI (ABO-102) became the company's second approved gene therapy in 2026 for mucopolysaccharidosis type IIIA. Abeona added APT-1011 (ABO-801), a Phase 3-ready orally disintegrating fluticasone formulation for eosinophilic esophagitis, in November 2026 and is advancing its SIR-T synthetic immune receptor platform, led by PSMA-targeted ABO-701 for advanced prostate cancer.